New Zealand To Cover Herceptin Breast Cancer Drug Despite Cost
This article was originally published in PharmAsia News
Executive Summary
Despite criticism the move would set a dangerous precedent, New Zealand's government said a 12-month course of a key breast cancer drug would be covered by the national health plan. The decision to cover Genentech's Herceptin (trastuzumab) would make the $109,000-a-year drug available to an estimated 300 women who get the disease every year. The opposition party said the action was tantamount to politicizing drug purchasing, since the nation's drug-buying agency had ruled against coverage. In New Zealand, about 40 new drugs are to be available within two years, each costing about as much as Herceptin. (Click here for more
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.